CJ Bioscience Inc

CJ Bioscience Inc has a market price of 7,710 KRW and a market cap of 100.73 billion KRW, with a price-to-book ratio of 1.88 and a price-to-tangible-book ratio of 1.88. The company's enterprise value to revenue is 30.1, and its enterprise value to EBITDA is -4.48, indicating a negative EBITDA. The company's liquidity is assessed as medium, with a current ratio of 3.6 and a debt-to-equity ratio of 0.19. The company's profitability is weak, with a return on equity of -44.75% and a return on assets of -33.18%. These metrics are below the industry median for Biotechnology & Medical Research, which typically shows positive returns on equity and assets. The company's operating income is -24.79 billion KRW, and its net income is -24.00 billion KRW, indicating significant losses. CJ Bioscience Inc's revenue is concentrated in its core business of microbial bioinformatics and microbiome-based healthcare services, with no disclosed geographic diversification in the provided data. The company's revenue is derived from a single primary segment, which may increase its exposure to market-specific risks. The company's growth trajectory is uncertain, with no disclosed revenue growth in the provided data. The company's operating cash flow is -23.42 billion KRW, and its free cash flow is -20.07 billion KRW, indicating a lack of cash generation. The company's capital expenditure is -75.93 million KRW, suggesting minimal investment in new projects. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag is that the company has negative net cash after subtracting total debt. The company's dilution potential is low, and no significant adjustments have been applied to its valuation metrics. Recent events include the company's rebranding from ChunLab Inc to CJ Bioscience Inc, reflecting a strategic shift towards microbiome-based healthcare services. No recent filings or transcripts are provided in the data to indicate further developments.